Johnson & Johnson (JNJ) said Monday it will present the latest data from the TAR-200 study to treat patients with Bacillus Calmette-Guerin-unresponsive, high-risk non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary disease at the American Urological Association on April 26.
The 12-month duration of response findings from cohort 2 of the phase 2b trial evaluating the TAR-200 monotherapy revealed a positive complete response rate, according to a statement.
The company said it will also present the first results from cohort 4 of the phase 2b trial for patients with papillary-only, high-risk non-muscle invasive bladder cancer.
Price: 157.83, Change: +0.35, Percent Change: +0.23
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。